Endo Announces FDA Decision Not to Include Vasopressin on 503B Bulks List

[In The News]

DUBLIN, March 1, 2019 /PRNewswire/ -- Endo International plc ("Endo") (NASDAQ: ENDP) today announced that the U.S. Food and Drug Administration (FDA) has determined that there is no clinical need to compound vasopressin under Section 503B of the Drug Quality and Security Act. As a result, ...

View the full article